vs

Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and NPK International Inc. (NPKI). Click either name above to swap in a different company.

NPK International Inc. is the larger business by last-quarter revenue ($75.2M vs $44.9M, roughly 1.7× AbCellera Biologics Inc.). On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 30.7%). NPK International Inc. produced more free cash flow last quarter ($5.8M vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 23.9%).

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

ABCL vs NPKI — Head-to-Head

Bigger by revenue
NPKI
NPKI
1.7× larger
NPKI
$75.2M
$44.9M
ABCL
Growing faster (revenue YoY)
ABCL
ABCL
+757.7% gap
ABCL
788.4%
30.7%
NPKI
More free cash flow
NPKI
NPKI
$50.3M more FCF
NPKI
$5.8M
$-44.6M
ABCL
Faster 2-yr revenue CAGR
ABCL
ABCL
Annualised
ABCL
112.3%
23.9%
NPKI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ABCL
ABCL
NPKI
NPKI
Revenue
$44.9M
$75.2M
Net Profit
$-8.9M
Gross Margin
37.7%
Operating Margin
-63.7%
16.7%
Net Margin
-19.9%
Revenue YoY
788.4%
30.7%
Net Profit YoY
73.9%
EPS (diluted)
$-0.03
$0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABCL
ABCL
NPKI
NPKI
Q4 25
$44.9M
$75.2M
Q3 25
$9.0M
$68.8M
Q2 25
$17.1M
$68.2M
Q1 25
$4.2M
$64.8M
Q4 24
$5.0M
$57.5M
Q3 24
$6.5M
$44.2M
Q2 24
$7.3M
$66.8M
Q1 24
$10.0M
$49.0M
Net Profit
ABCL
ABCL
NPKI
NPKI
Q4 25
$-8.9M
Q3 25
$-57.1M
$5.7M
Q2 25
$-34.7M
$8.7M
Q1 25
$-45.6M
$10.0M
Q4 24
Q3 24
$-51.1M
$-174.3M
Q2 24
$-36.9M
$8.0M
Q1 24
$-40.6M
$7.3M
Gross Margin
ABCL
ABCL
NPKI
NPKI
Q4 25
37.7%
Q3 25
31.9%
Q2 25
36.9%
Q1 25
39.0%
Q4 24
39.2%
Q3 24
27.5%
Q2 24
37.2%
Q1 24
36.0%
Operating Margin
ABCL
ABCL
NPKI
NPKI
Q4 25
-63.7%
16.7%
Q3 25
-851.8%
13.2%
Q2 25
-290.2%
17.0%
Q1 25
-1479.6%
20.9%
Q4 24
20.2%
Q3 24
-1439.4%
2.8%
Q2 24
-1276.2%
18.7%
Q1 24
-551.5%
14.2%
Net Margin
ABCL
ABCL
NPKI
NPKI
Q4 25
-19.9%
Q3 25
-637.8%
8.2%
Q2 25
-203.3%
12.7%
Q1 25
-1077.2%
15.4%
Q4 24
Q3 24
-785.4%
-394.3%
Q2 24
-504.3%
12.0%
Q1 24
-408.0%
14.9%
EPS (diluted)
ABCL
ABCL
NPKI
NPKI
Q4 25
$-0.03
$0.17
Q3 25
$-0.19
$0.07
Q2 25
$-0.12
$0.10
Q1 25
$-0.15
$0.11
Q4 24
$0.10
Q3 24
$-0.17
$-1.99
Q2 24
$-0.13
$0.09
Q1 24
$-0.14
$0.08

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABCL
ABCL
NPKI
NPKI
Cash + ST InvestmentsLiquidity on hand
$128.5M
$5.1M
Total DebtLower is stronger
$16.9M
Stockholders' EquityBook value
$966.9M
$351.2M
Total Assets
$1.4B
$441.8M
Debt / EquityLower = less leverage
0.05×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABCL
ABCL
NPKI
NPKI
Q4 25
$128.5M
$5.1M
Q3 25
$83.2M
$35.6M
Q2 25
$92.4M
$26.0M
Q1 25
$159.3M
$20.8M
Q4 24
$156.3M
$17.8M
Q3 24
$126.6M
$42.9M
Q2 24
$148.3M
$35.1M
Q1 24
$123.6M
$37.7M
Total Debt
ABCL
ABCL
NPKI
NPKI
Q4 25
$16.9M
Q3 25
$9.5M
Q2 25
$9.3M
Q1 25
$8.1M
Q4 24
$7.7M
Q3 24
$14.0M
Q2 24
$58.0M
Q1 24
$77.4M
Stockholders' Equity
ABCL
ABCL
NPKI
NPKI
Q4 25
$966.9M
$351.2M
Q3 25
$964.0M
$333.9M
Q2 25
$1.0B
$328.8M
Q1 25
$1.0B
$326.9M
Q4 24
$1.1B
$326.5M
Q3 24
$1.1B
$316.5M
Q2 24
$1.1B
$426.6M
Q1 24
$1.1B
$421.6M
Total Assets
ABCL
ABCL
NPKI
NPKI
Q4 25
$1.4B
$441.8M
Q3 25
$1.4B
$404.5M
Q2 25
$1.4B
$393.7M
Q1 25
$1.3B
$390.0M
Q4 24
$1.4B
$393.7M
Q3 24
$1.4B
$389.6M
Q2 24
$1.4B
$624.8M
Q1 24
$1.5B
$640.8M
Debt / Equity
ABCL
ABCL
NPKI
NPKI
Q4 25
0.05×
Q3 25
0.03×
Q2 25
0.03×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.14×
Q1 24
0.18×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABCL
ABCL
NPKI
NPKI
Operating Cash FlowLast quarter
$-34.7M
$18.0M
Free Cash FlowOCF − Capex
$-44.6M
$5.8M
FCF MarginFCF / Revenue
-99.4%
7.6%
Capex IntensityCapex / Revenue
21.9%
16.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-174.1M
$26.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABCL
ABCL
NPKI
NPKI
Q4 25
$-34.7M
$18.0M
Q3 25
$-52.6M
$24.7M
Q2 25
$-32.4M
$21.4M
Q1 25
$-11.6M
$8.8M
Q4 24
$-108.6M
$-4.1M
Q3 24
$-28.9M
$2.8M
Q2 24
$-30.0M
$27.6M
Q1 24
$-41.7M
$11.9M
Free Cash Flow
ABCL
ABCL
NPKI
NPKI
Q4 25
$-44.6M
$5.8M
Q3 25
$-61.5M
$12.0M
Q2 25
$-45.8M
$9.7M
Q1 25
$-22.2M
$-1.2M
Q4 24
$-187.0M
$-17.7M
Q3 24
$-47.4M
$-6.7M
Q2 24
$-50.1M
$21.0M
Q1 24
$-65.8M
$-1.9M
FCF Margin
ABCL
ABCL
NPKI
NPKI
Q4 25
-99.4%
7.6%
Q3 25
-687.0%
17.4%
Q2 25
-267.9%
14.3%
Q1 25
-524.0%
-1.8%
Q4 24
-3702.8%
-30.8%
Q3 24
-728.4%
-15.2%
Q2 24
-683.8%
31.4%
Q1 24
-661.5%
-3.9%
Capex Intensity
ABCL
ABCL
NPKI
NPKI
Q4 25
21.9%
16.3%
Q3 25
99.7%
18.5%
Q2 25
78.2%
17.1%
Q1 25
251.1%
15.5%
Q4 24
1552.7%
23.6%
Q3 24
284.6%
21.4%
Q2 24
274.6%
9.9%
Q1 24
242.5%
28.3%
Cash Conversion
ABCL
ABCL
NPKI
NPKI
Q4 25
Q3 25
4.37×
Q2 25
2.47×
Q1 25
0.88×
Q4 24
Q3 24
Q2 24
3.43×
Q1 24
1.64×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ABCL
ABCL

Segment breakdown not available.

NPKI
NPKI

Rental Revenue$34.8M46%
Products$25.5M34%
Services$14.9M20%

Related Comparisons